{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"9.2","value":"92.4"},{"groupId":"OG001","spread":"7.0","value":"91.7"}]}],"title":"Screening"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"11.4","value":"0.0"},{"groupId":"OG001","spread":"7.5","value":"0.4"}]}],"title":"Follow-up"}],"denoms":[{"counts":[{"groupId":"OG000","value":"46"},{"groupId":"OG001","value":"47"}],"units":"Participants"}],"description":"The Karnofsky performance status is a way to quantify cancer patients' general well-being and activities of daily life and runs from 100 to 0, where 100 is \"perfect\" health and 0 is death.","dispersionType":"Standard Deviation","groups":[{"description":"bortezomib (Velcade) 1.6 mg/m² bolus injection on Days 1, 8, 15 and 22 every 5 weeks for 4 cycles","id":"OG000","title":"Bortezomib"},{"description":"no treatment, observation only","id":"OG001","title":"Non-treated Control"}],"paramType":"MEAN","populationDescription":"FAS included all the randomized subjects who were eligible for efficacy analysis, that is, excluding subjects who did not have baseline and/or post-baseline data. \"N\" (number of subjects analyzed) signifies the subjects evaluable this measure. Missing data was imputed by last observation carried forward (LOCF) method.","reportingStatus":"POSTED","timeFrame":"Baseline up to end of study (approximately 4 years 7 months)","title":"Karnofsky Performance Status","type":"SECONDARY","unitOfMeasure":"Units on a scale"}